DNMT1
DNA methyltransferase 1 (DNMT1) is a DNA methyltransferase and a central target in studies of DNA methylation–associated disease mechanisms.
DNA methyltransferase 1 (DNMT1) is a DNA methyltransferase and a central target in studies of DNA methylation–associated disease mechanisms. The recent literature supplied here places DNMT1 within a single broad theme of epigenetic disease mechanisms, in which altered DNMT1 expression or activity is associated with cancer biology, metabolic dysfunction, fibrosis, vascular disease, and neurodegeneration. These studies examine DNMT1 alongside DNA methylation, global DNA methylation, DNMT3A, ubiquitin-specific peptidase 7 (USP7), and signaling or metabolic pathways involving TP53, Hippo signaling, the urea cycle, propionate metabolism, and glycolytic reprogramming.
DNMT1 is being investigated both as a mechanistic regulator and as a pharmaceutical target. Hypomethylating strategies, including DNMT1 inhibitors and the investigational agent NTX-301, are being evaluated in relation to apoptosis and cancer-cell responses, while other studies examine indirect modulation of DNMT1 through USP7, stress signaling, or candidate drugs such as sotagliflozin and pirfenidone. The reported findings are disease-specific and include associations with chemotherapy response, tumor recurrence, fibrosis, diabetic complications, fatty-liver disease, and Parkinsonism; they do not establish a single therapeutic mechanism applicable across these conditions.
Where the papers sit
10 papers from the last 6 months study DNMT1 directly · updated from PubMed 1 Nov 2026
Study type 0 clinical trials · 3 human data · 7 preclinical
Themes 3 themes
-
Pathological DNA Methylation
DNMT1 is being mapped as a context-dependent link between aberrant methylation, metabolism and treatment response. USP7-centered complexes recur: pirfenidone disrupts USP7/DNMT1 to raise GLIS1 in diabetic kidney fibrosis, while HSP90α-USP7-DNMT1 drives HCC recurrence through ACSS3 and propionate metabolism. Other work connects DNMT1 methylation of FBXO32 to Myc stability and glycolytic reprogramming in diabetic retinopathy, and QDPR silencing to lung adenocarcinoma chemotherapy response. These studies support mechanism-specific targeting, but span complications, recurrence and drug response without a unified therapeutic direction.
4 papers · 40%
-
Epigenetic Cancer Therapy
DNMT1 modulation is being paired with broader epigenetic or metabolic interventions to disrupt cancer-cell survival. Sotagliflozin links DNMT1 and class I/II HDAC changes to viability effects in breast cancer, while NTX-301 reprograms epigenetic and Hippo signaling in venetoclax-resistant disease. BET plus DNMT inhibition extends this strategy to transdifferentiated prostate cancer by targeting survival pathways. Evidence remains preclinical across distinct tumor contexts, leaving durability and clinical selectivity open.
3 papers · 30%
-
Natural Compounds and DNA Methylation
Natural compounds are being explored as DNMT1-directed ways to reverse pathological DNA methylation in cancer and metabolic liver disease. Docking and molecular-dynamics analyses nominate phytochemicals and PlantCyc compounds as candidate inhibitors, with breast cancer providing the main anticancer context. Jianpi Qinghua granule extends the question to metabolic dysfunction-associated fatty liver disease by linking DNMT regulation to the urea cycle. The evidence is predominantly computational or mechanistic, so biochemical target engagement and in vivo efficacy remain open.
3 papers · 30%
Papers
The 10 papers from the last 6 months that study DNMT1 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Pathological DNA Methylation (4)
- DNMT1 is associated with QDPR downregulation and chemotherapy response in lung adenocarcinoma. Medical oncology (Northwood, London, England) · 1 Sept 2026 PMID 42678580
- HSP90α-USP7-DNMT1 axis drives HCC recurrence after microwave ablation by disrupting ACSS3-mediated propionate metabolism. Molecular therapy : the journal of the American Society of Gene Therapy · 27 Jun 2026 PMID 42363602
- DNMT1 methylates E3 ligase FBXO32 to regulate Myc stability and glycolytic reprogramming in diabetic retinopathy associated endothelial cells. Journal of bioenergetics and biomembranes · 25 Jun 2026 PMID 42348038
- Pirfenidone Elevates GLIS1 by Disrupting the USP7/DNMT1 Complex and Alleviates Renal Fibrosis in Diabetic Kidney Disease Through ROS Reduction and TGF-β1/Smad Signaling Inhibition. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 20 May 2026 PMID 42159303
Epigenetic Cancer Therapy (3)
- Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells. Cell biology international · 1 Sept 2026 PMID 42677956
- Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer. JCI insight · 11 Aug 2026 PMID 42579341
- The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42439804
Natural Compounds and DNA Methylation (3)
- Phytochemical modulation of DNMT1-mediated DNA methylation: computational insights into breast cancer. Journal of molecular modeling · 18 Oct 2026 PMID 42891767
- In silico identification of DNMT1 inhibitors from the PlantCyc database through computational approach to assess the anti-cancer potential of nutraceutical compounds in breast cancer. Journal of molecular graphics & modelling · 21 Jun 2026 PMID 42323936
- Mechanism of Jianpi Qinghua granule in ameliorating metabolic dysfunction-associated fatty liver disease by targeting the DNMT-urea cycle axis. Journal of ethnopharmacology · 10 May 2026 PMID 42107753
By study type
Human data, design not indexed (3)
- Phytochemical modulation of DNMT1-mediated DNA methylation: computational insights into breast cancer. Journal of molecular modeling · 18 Oct 2026 PMID 42891767
- DNMT1 methylates E3 ligase FBXO32 to regulate Myc stability and glycolytic reprogramming in diabetic retinopathy associated endothelial cells. Journal of bioenergetics and biomembranes · 25 Jun 2026 PMID 42348038
- In silico identification of DNMT1 inhibitors from the PlantCyc database through computational approach to assess the anti-cancer potential of nutraceutical compounds in breast cancer. Journal of molecular graphics & modelling · 21 Jun 2026 PMID 42323936
Preclinical: animal, cell and lab studies (7)
- DNMT1 is associated with QDPR downregulation and chemotherapy response in lung adenocarcinoma. Medical oncology (Northwood, London, England) · 1 Sept 2026 PMID 42678580
- Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells. Cell biology international · 1 Sept 2026 PMID 42677956
- Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer. JCI insight · 11 Aug 2026 PMID 42579341
- The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42439804
- HSP90α-USP7-DNMT1 axis drives HCC recurrence after microwave ablation by disrupting ACSS3-mediated propionate metabolism. Molecular therapy : the journal of the American Society of Gene Therapy · 27 Jun 2026 PMID 42363602
- Pirfenidone Elevates GLIS1 by Disrupting the USP7/DNMT1 Complex and Alleviates Renal Fibrosis in Diabetic Kidney Disease Through ROS Reduction and TGF-β1/Smad Signaling Inhibition. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 20 May 2026 PMID 42159303
- Mechanism of Jianpi Qinghua granule in ameliorating metabolic dysfunction-associated fatty liver disease by targeting the DNMT-urea cycle axis. Journal of ethnopharmacology · 10 May 2026 PMID 42107753
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-09-16. Drafted by language models from published abstracts; not medical advice.